

treatment planning involves the direct input of target volumes and organs at risk (OAR) using cross-sectional images from computed tomography (CT) and magnetic resonance imaging (MRI). Technical advances in the radiation delivery devices as well as ancillary equipments such as radiotherapy treatment planning systems and on-board imaging devices enable the precise delivery of external beam radiotherapy. Intensity-modulated radiation therapy (IMRT) has proven to have a significant dosimetric advantage in comparison with conventional treatment planning for various malignancies including gynecologic cancers (1).

Although improvements have been made in treatment equipments and techniques, determination of both target volumes and OAR has not been well standardized. In particular, contouring of the clinical target volume (CTV) of regional lymph nodes requires thorough understanding of both the distribution patterns of microscopic metastases and anatomic features on cross-sectional images. Lack of a standardized contouring protocol may result in considerable variation in contouring (2). Therefore, a global consensus is needed for the standard CTV for regional nodes in cervical cancer in order to optimize the delivery of high precision external beam radiotherapy including IMRT.

In Europe, the nodal CTV was first standardized for head and neck cancers (3,4). CTV standardization has also progressed in prostate cancer (5) and anorectal cancers (6) in the USA. For uterine cancers, the Radiation Therapy Oncology Group (RTOG) (7) and UK investigators (8,9) have also recently published their guidelines.

A working subgroup to establish a guideline delineating the CTV for cervical cancer was organized within the Radiation Therapy Study Group (RTSG) of the Japan Clinical Oncology Group (JCOG). The guideline is intended for use by Japanese clinicians. Additionally, the guideline is also designed to be utilized by researchers conducting prospective multi-institutional studies using high precision external beam radiotherapy including IMRT for uterine cervical cancer. This paper describes the process by which the guideline was developed and presents the guideline for contouring pelvic node CTV in cervical cancer.

## PATIENTS AND METHODS

A working subgroup to establish consensus-based guideline on CTV for uterine cervical cancer was formulated by the JCOG RTSG in July 2008. The working subgroup consisted of seven radiation oncologists practicing in Japan. The committee met twice and extensive discussions were conducted via electronic mail (e-mail) throughout the entire process. The working group first addressed pelvic nodal CTV.

First, a set of hard copies of actual CT images of a cervical cancer patient were sent to each member. Each performed a contouring procedure of the pelvic nodal CTV on the CT images. At the first meeting held in November 2008, the members brought the contoured images and compared to

identify areas of discrepancy in the nodal CTV delineation. A preliminary draft of the guideline was then formulated based on published studies (T.T.). Previously published guidelines on CTV delineation (7–9), imaging studies (10–14), as well as gynecologic surgery series (15–17) (reviewing the distribution of pelvic nodal metastases), and papers and textbooks of pelvic anatomy related to images (18,19) were reviewed. The draft included basic criteria, definitions and a preliminary atlas of the nodal CTV. In the draft, the nodal CTV was subdivided into five regions, i.e. common iliac, external iliac, internal iliac, obturator and presacral. Anatomical structures bordering each lymph node region were defined for six directions; anterior, posterior, lateral, medial, cranial and caudal (14). An atlas of the nodal CTV was drawn using a commercial radiotherapy planning system (Eclipse; External Beam Planning 8.1.20, Varian Medical Systems) according to the stated definitions. The preliminary draft was intensively reviewed and discussions held over several months through multiple e-mail discussions. The document was extensively revised. Next, CT/MRI image sets of cervical cancer patients who were assessed as having pelvic node metastases (short axis diameter of >10 mm) were collected from the committee members' institutions. With these data, anatomic distributions of metastatic nodes within each lymph node region on transverse images were analyzed to assess whether the preliminary CTV definition was adequate. On the basis of these results, a final draft of the guideline was confirmed in the second face-to-face working group meeting in April 2009. The version was presented and reviewed at the JCOG RTSG meeting in June 2009, and the JCOG Gynecologic Cancer Study Group (GCSG) meeting in July 2009. The draft was reviewed and minor revisions were proposed by radiation oncologists and gynecologic oncologists at these meetings. In response to those, minor revisions were made, and any discrepancies remaining were discussed and consolidated. A final draft of the guideline on nodal CTV contouring was established in September 2009.

## RESULTS

As a basic criterion, the lymph node CTV was defined as the area encompassed by a 7 mm margin around the applicable pelvic vessels (artery and vein). In addition to the aforementioned areas, some modifications were made in each nodal area. Since there are no visible major vessels in the presacral area, the definition for the presacral node region was based on the bony and muscle anatomy.

The CTV was modified to exclude bones and muscles. We determined that the bowel could not be excluded routinely due to the daily changes in its shape and position. Table 1 shows the nodal CTV definitions which describe the anatomical boundary of each subcategorized node group in the pelvis. Definitions were made for the following six directions on the 3D images: anterior, posterior, lateral, medial, cranial

**Table 1.** Clinical target volume definition on pelvic nodes related to anatomic landmarks for cervical cancer

Node chains	Cranial margin	Caudal margin	Anterior margin	Posterior margin	Lateral margin	Medial margin
Common iliac	Aortic bifurcation or L4-5 space	Common iliac a bifurcation	7 mm anterior to a/v	L5—sacrum (adequately involve adipose connective tissue between lateral surface of vertebral body and psoas m <sup>a</sup> )	7 mm lateral to a/v (expanding to psoas major m)	—
External iliac	Common iliac a bifurcation	Superior aspect of femoral head	7 mm anterior to a/v (connecting to obturator region)	7 mm posterior to a/v (connecting to obturator region)	7 mm lateral to a/v (expanding to psoas major m or iliacus m)	7 mm medial to a/v uterus, ovary, bowel, ureter or bladder
Internal iliac	Common iliac a bifurcation	Cranial section of coccygeus m, spine of ischium or uterine a/v (connecting to parametrial region)		Cranial level: wing of sacrum  Middle-caudal level: anterior edge of piriformis m or inferior gluteal a/v	Cranial level: psoas m, iliacs m or lateral edge of sacroiliac joint  Middle level: Iliac bone, psoas m or medial edge of Iliacus m  Caudal level: obturator internus m or piriformis m	7 mm medial to a/v bowel, uterus or ovary
Obturator	Caudal section of sacroiliac joint (connecting to internal iliac region)	Superior part of obturator foramen	Cranial-middle level: connecting to external iliac region  Caudal level: posterior edge of pubic bone	Cranial-middle level: connecting to internal iliac region  Caudal level: posterior edge of obturator internus m	Obturator internus m, iliacus m, psoas m or iliac bone	Bladder, uterus or bowel
Presacral	Common iliac a bifurcation	Lower level of S2 or cranial section of piriformis m	10 mm anterior to sacrum	L5—sacrum	Piriformis m (connecting to external or internal iliac region)	—

a, artery; a/v, artery and vein; m, muscle.

<sup>a</sup>Even in patients with low adipose connective tissue in this space, posterior margin should also extend to posterior edge of vertebral body.

and caudal. Figure 1 is an atlas of the pelvic nodal CTV contouring which applies these definitions (Fig. 2). Digitally reconstructed radiograph with pelvic node CN and vessels are shown in Figure 2.

**DISCUSSION**

We established a guideline and an atlas that defined the pelvic nodal CTV in external beam radiotherapy for cervical cancer. This document underwent extensive revision by a committee consisting of seven radiation oncologists considered experts in cervical cancer treatment in Japan. In addition, this guideline was also critically reviewed by radiation oncologists other than the committee members and the gynecologic oncologists in the JCOG. Therefore, this may be considered a consensus-based guideline in Japan.

Margins are designed around blood vessels which serve as good surrogate targets for regional nodes (7,8,12,20). Chao and Lin (12) studied the pelvic node distribution in patients

with uterine cervical cancer who underwent lymphangiography. They showed that 10–15 mm margins adequately covered the pelvic node regions. However, the working group felt that these margins were unnecessarily expansive. Taylor et al. (8) demonstrated using the intravenous ultra-small particles of iron oxide (USPIO) MRI that a 7 mm margin around the vessels achieved 88% nodal coverage in the assessed regions. The RTOG guideline also employed this basic definition of a 7 mm margin (7). In addition to that, Taylor et al. (8) modified the definition and achieved a coverage ratio of 99%. We considered this methodology to be clinically appropriate and adopted it into our definition. As the RTOG guideline, the bones and muscles were excluded from the CTV in the present guideline (7). However, the bowel was not routinely excluded in contrast to the RTOG guideline. We accounted for daily changes in bowel configuration. Further studies are needed to address bowel exclusion with image-guided radiotherapy devices, such as the on-board cone beam CT system.

Downloaded from ascelibrary.org by National Cancer Center Library on May 9, 2015

For the common iliac region, two questions arose in the process of arriving at a consensus. The first issue pertained to defining the cranial margin. Ideally, the region should be defined based on the blood vessel anatomy at the level of common iliac arterial bifurcation. However, a key principle of the present guideline was not to deviate significantly from the conventional 2D whole pelvic field. The RTOG guideline also maintained a definition based on the bone anatomy (7). Therefore, we provided two definitions, one based on blood vessels and the other based on bone anatomy. A therapeutic challenge identified in several studies lies in treating nodal recurrence around the cranial margin of the pelvic field (21). The delivery of secondary radiotherapy with an appropriate target volume in such a situation is technically difficult. In addition, categorizing the recurrence as a regional (pelvic recurrence) or distant (para-aortic nodal) failure may not be possible when the previous pelvic field was constructed based on the bony anatomy. Therefore, we recommended that the definition based on vessel anatomy be solely employed in future revisions of the guideline. A second issue was the posterior margin of the CTV. In contrast to the RTOG guideline (7), the CTV in the present guideline

involves adipose connective tissue between the iliopsoas muscles and the lateral surface of the vertebral body. This is based on our present analysis of CT/MRI images of the actual patients who had pelvic nodal metastases. The analysis revealed that some patients had lymphadenopathy in this area. In the atlas of Taylor et al. (8,9), the area is also included in the CTV for common iliac nodes. However, this area has not been covered to the same extent when a conventional 2D lateral field is used. Therefore, the clinical appropriateness of treatment planning using conventional 2D lateral portals should be re-evaluated in light of actual failure rates.

In the external iliac region, the caudal margin was defined as the level of the superior border of the femoral head. This definition is the same as that of the RTOG guideline (7). According to this anatomical definition, the margin should move caudally until it reaches the level at the junction with the femoral vessels or the level at the intersection with the transverse abdominal muscles. However, in this guideline, the superior border of the femoral head was selected as the caudal margin for the following two reasons. One reason is that the incidence of nodal metastases reported in surgical





Figure 1. An atlas of clinical target volume (CTV) for pelvic lymph nodes for uterine cervical cancer.




series is relatively low (15–17). Sakuragi et al. (16) analyzed the distribution patterns of metastatic nodes in 208 patients with Stage I/II cervical cancer treated with radical hysterectomy and pelvic node dissection. They reported that only 3.8% of the patients had pelvic nodal metastases in the external iliac region (16). Second, if the caudal margin extends to a lower level, a large area of the femoral head and neck would be included in the treated volume resulting from the CTV definition. Furthermore, this situation would be significant when the conventional technique is applied. In contrast, portals resulting from the present definition would be far from those produced using conventional 2D fields, which always include the lower aspect of the region. The appropriateness of the present definition should be evaluated clinically by investigating whether the rates of nodal recurrence increase in the excluded area. Exceptionally, when a patient has nodal metastases (either pathologically conformed or clinically) in the cranial level of this chain, we recommend nodal CN should be extended more caudally.

The present CTV definition of the internal iliac node region differs significantly from the guideline of the RTOG. Our analyses on the actual distribution of enlarged

nodes demonstrated that a significant number of enlarged nodes were observed from the lateral margin of the adipose connective tissue to the medial surface of the psoas muscle, or at the level of the sacral wing tips, which were not included in the RTOG guideline (7). The conventional 2D fields usually cover this area. Taylor's guideline also employed a similar definition to ours (8,9). Therefore, the current RTOG definition on lateral expansion of the CTV for the internal iliac node may be insufficient. In the present guideline, the parametrial lymph node region was not defined. This will be included in the guideline for primary tumor CTV.

Defining the caudal extent of the obturator node region was another area of discrepancy addressed by the present guideline. Referring to the anatomical definition, the obturator nodes distribute into the anatomical level where the obturator vessels penetrate the obturator foramens. The surgical procedure manual published by the Japanese Gynecologic Oncology Group (JGOG) indicates that the obturator node dissection should be performed caudally to the level of the obturator foramens (22). In cases of external beam radiotherapy, the conventional 2D pelvic fields also include the foramens. Therefore, in our current definition,




the upper level of the foramen is also included in the nodal CTV.

The presacral node region was defined similarly to previously published guidelines (7–9). A study with MRI using USPIO revealed that the lymph node was only sparsely distributed in this area and CTV coverage was not required extensively (8). The working group discussed why the conventional 2D lateral field covers extensively entire sacral surface. We concluded that conventional lateral field was primarily intended to achieve adequate coverage of the parametrial tissues. The parametrial tissues will be included in the CTV for primary tumor (9,23).

The present guideline was intended to be applied irrespective of pelvic nodal status. In head and neck cancers, the nodal CTV guideline was proposed separately for node-positive and post-operative patients (4). We expect this guideline could be applied to patients with pelvic nodal metastases with individual arrangement, e.g. appropriate margin within adhered muscles or bones.

The presently developed guideline provides standard definitions for nodal CTV in cervical cancer to aid in treatment planning for highly precise external beam radiotherapy including IMRT. The guideline may also be utilized in prospective multi-institutional clinical trials to avoid



**Figure 2.** Digitally reconstructed radiographs showing CTV for pelvic lymph nodes (yellow) and vessels (orange); (A) anterior view and (B) lateral view.

variation in CTV determination. This guideline is a work in progress. It will continue to be modified as new clinical findings and opinions from functional imaging and sentinel lymph node studies become available. Guideline defining the CTV for primary lesions in the cervical cancer is currently under development.

### Acknowledgements

The authors thank all the gynecologic oncologists of the JCOG Gynecologic Cancer Study Group (GCSG) for their advice and expertise.

### Funding

This study was supported by a Grant-in-Aid for Cancer Research (18-11, 20-5), and the Japan Society for the Promotion of Sciences (no. 21591614).

### Conflict of interest statement

None declared.

### References

- Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. *Int J Radiat Oncol Biol Phys* 2002;52:1330–7.
- Weiss E, Richter S, Krauss T, Metzeltin SI, Hille A, Pradier O, et al. Conformal radiotherapy planning of cervix carcinoma: differences in the delineation of the clinical target volume. A comparison between gynaecologic and radiation oncologists. *Radiother Oncol* 2003;67:87–95.
- Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. *Radiother Oncol* 2003;69:227–36.
- Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. *Radiother Oncol* 2006;79:15–20.
- Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2010;76:361–8.
- Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. *Int J Radiat Oncol Biol Phys* 2009;74:824–30.
- Small W, Jr, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. *Int J Radiat Oncol Biol Phys* 2008;71:428–34.
- Taylor A, Rockall AG, Reznick RH, Powell ME. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys* 2005;63:1604–12.
- Taylor A, Rockall AG, Powell ME. An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. *Clin Oncol (R Coll Radiol)* 2007;19:542–50.
- Park JM, Charnsangavej C, Yoshimitsu K, Herron DH, Robinson TJ, Wallace S. Pathways of nodal metastasis from pelvic tumors: CT demonstration. *Radiographics* 1994;14:1309–21.
- Martinez-Monge R, Fernandes PS, Gupta N, Gahbauer R. Cross-sectional nodal atlas: a tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. *Radiology* 1999;211:815–28.
- Chao KS, Lin M. Lymphangiogram-assisted lymph node target delineation for patients with gynecologic malignancies. *Int J Radiat Oncol Biol Phys* 2002;54:1147–52.
- Portaluri M, Bambace S, Perez C, Angone G. A three-dimensional definition of nodal spaces on the basis of CT images showing enlarged nodes for pelvic radiotherapy. *Int J Radiat Oncol Biol Phys* 2005;63:1101–7.
- Dinniwell R, Chan P, Czarnota G, Haider MA, Jhaveri K, Jewett M, et al. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging. *Int J Radiat Oncol Biol Phys* 2009;74:844–51.

15. Benedetti-Panici P, Maneschi F, Scambia G, Greggi S, Cutillo G, D'Andrea G, et al. Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. *Gynecol Oncol* 1996;62:19–24.
16. Sakuragi N, Satoh C, Takeda N, Hareyama H, Takeda M, Yamamoto R, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. *Cancer* 1999;85:1547–54.
17. Matsumoto K, Yoshikawa H, Yasugi T, Onda T, Nakagawa S, Yamada M, et al. Distinct lymphatic spread of endometrial carcinoma in comparison with cervical and ovarian carcinomas. *Cancer Lett* 2002;180:83–9.
18. Lengele B, Scalliet P. Anatomical bases for the radiological delineation of lymph node areas. Part III: pelvis and lower limbs. *Radiother Oncol* 2009;92:22–33.
19. Bo WJ, Carr JJ, Krueger WA, Wolfman NT, Bowden RL. Female pelvis. In: Bo WJ, Carr JJ, Krueger WA, Wolfman NT, Bowden RL, editors. *Basic Atlas of Sectional Anatomy with Correlated Imaging*. 4th edn. Philadelphia: Elsevier Saunders 2007;313–70.
20. Uno T, Isobe K, Ueno N, Kobayashi H, Sanayama Y, Mitsuhashi A, et al. Vessel-contouring-based pelvic radiotherapy in patients with uterine cervical cancer. *Jpn J Clin Oncol* 2009;39:376–80.
21. Beadle BM, Jhingran A, Yom SS, Ramirez PT, Eifel PJ. Patterns of regional recurrence after definitive radiotherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* (in press).
22. Isonishi S, Kita T, Tabata T, Terauchi F, Nakayama H, Mizutani K. Radical hysterectomy. In: Sakuragi N, editor. *JGOG Surgical Procedure Manual*. Tokyo: Japanese Gynecologic Oncology Group 2007;6.
23. Greer BE, Koh WJ, Figge DC, Russell AH, Cain JM, Tamimi HK. Gynecologic radiotherapy fields defined by intraoperative measurements. *Gynecol Oncol* 1990;38:421–4.

CLINICAL INVESTIGATION

Lung

VARIATIONS IN TARGET VOLUME DEFINITION FOR POSTOPERATIVE  
RADIOTHERAPY IN STAGE III NON-SMALL-CELL LUNG CANCER: ANALYSIS OF  
AN INTERNATIONAL CONTOURING STUDY

FEMKE O. B. SPOELSTRA, M.D.,\* SURESH SENAN, M.R.C.P., F.R.C.R., PH.D.,\* CECILE LE PÉCHOUX, M.D.,†  
SATOSHI ISHIKURA, M.D., PH.D.,‡ FRANCESC CASAS, M.D.,§ DAVID BALL, M.B., B.S., M.D.,  
F.R.A.N.Z.C.R.,¶ ALLAN PRICE, F.R.C.P., F.R.C.R., PH.D.,|| DIRK DE RUYSSCHER, M.D., PH.D.,\*\*  
AND JOHN R. VAN SÖRNSEN DE KOSTE, PH.D.,\* LUNG ADJUVANT RADIOTHERAPY TRIAL INVESTIGATORS GROUP

\*Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands, †Radiation Oncology, Institut Gustave Roussy, Villejuif, France, ‡Clinical Trials and Practice Support Division, National Cancer Center, Tokyo, Japan, §Radiation Oncology, Hospital Clínic, Barcelona, Spain, ¶Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, ||Radiation Oncology, Western General Hospital, Edinburgh, United Kingdom, and \*\*Radiation Oncology (Maastricht clinic), Maastricht University Medical Center, Grow, Maastricht, The Netherlands

**Purpose:** Postoperative radiotherapy (PORT) in patients with completely resected non-small-cell lung cancer with mediastinal involvement is controversial because of the failure of earlier trials to demonstrate a survival benefit. Improved techniques may reduce toxicity, but the treatment fields used in routine practice have not been well studied. We studied routine target volumes used by international experts and evaluated the impact of a contouring protocol developed for a new prospective study, the Lung Adjuvant Radiotherapy Trial (Lung ART).

**Methods and Materials:** Seventeen thoracic radiation oncologists were invited to contour their routine clinical target volumes (CTV) for 2 representative patients using a validated CD-ROM-based contouring program. Subsequently, the Lung ART study protocol was provided, and both cases were contoured again. Variations in target volumes and their dosimetric impact were analyzed.

**Results:** Routine CTVs were received for each case from 10 clinicians, whereas six provided both routine and protocol CTVs for each case. Routine CTVs varied up to threefold between clinicians, but use of the Lung ART protocol significantly decreased variations. Routine CTVs in a postlobectomy patient resulted in  $V_{20}$  values ranging from 12.7% to 54.0%, and Lung ART protocol CTVs resulted in values of 20.6% to 29.2%. Similar results were seen for other toxicity parameters and in the postpneumectomy patient. With the exception of upper paratracheal nodes, protocol contouring improved coverage of the required nodal stations.

**Conclusion:** Even among experts, significant interclinician variations are observed in PORT fields. Inasmuch as contouring variations can confound the interpretation of PORT results, mandatory quality assurance procedures have been incorporated into the current Lung ART study. © 2010 Elsevier Inc.

Non-small-cell lung cancer, Resection, Postoperative radiotherapy, Target volumes, Interobserver variability.

INTRODUCTION

The role of postoperative radiotherapy (PORT) in patients with completely resected non-small-cell lung cancer is still controversial. Despite increasing local control rates (1–3), a large meta-analysis has shown a detrimental impact of PORT on overall survival, particularly in patients with no mediastinal involvement (4). However, the meta-analysis has been criticized because the studies included may have led to higher morbidity and mortality rates resulting from the use of two-dimensional radiotherapy techniques, high

doses and fraction sizes, and large-field radiotherapy that incorporated the entire mediastinum using suboptimal radiotherapy techniques and lacking modern verification procedures or trial quality assurance (QA) (5–7).

Recently, data from the Surveillance, Epidemiology, and End Results (SEER) database and an unplanned subgroup analysis of a Phase III trial suggested that PORT using more recent techniques may improve survival in patients with resected N2 disease (8, 9). This has renewed interest in evaluating PORT in this patient category. A new international Phase

Reprint requests to: F.O.B. Spoelstra, M.D., VU University Medical Center, Department of Radiation Oncology, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Tel: (+31) 20-4440414; Fax: (+31) 20-4440410; E-mail: f.spoelstra@vumc.nl

Presented at the 12<sup>th</sup> International Association for the Study of Lung Cancer World Conference on Lung Cancer, September 2–6,

2007, and at the American Society Clinical Oncology annual meeting, June 1–5, 2007.

Conflict of interest: none.

Received Dec 19, 2008, and in revised form Feb 17, 2009. Accepted for publication Feb 27, 2009.

III trial, the Lung Adjuvant Radiotherapy Trial (Lung ART), has been activated to compare PORT with no PORT in patients with completely resected N2 disease, irrespective of the use of chemotherapy (10). However, the cornerstone of radiotherapy is the use of consistent and reproducible target definitions, and current literature suggested that many groups were using target volumes defined in the era of two-dimensional radiotherapy (7, 11). In addition, large interobserver variations in target volumes have been observed in patients presenting with lung tumors that were visible on CT or positron emission tomography (PET)—CT scans (12–15). It is conceivable that the lack of identifiable tumor after a radical resection may potentially result in even greater variations. In the Lung ART study, the use of conformal radiotherapy is mandatory, and the target volumes are tailored based on both radiologic and surgical findings. As a prelude to Lung ART, the present study was designed to identify potential variations in target definitions in an international setting. In addition, the ability of the Lung ART protocol to reduce the potential variations in defining clinical target volumes (CTVs) was studied.

## METHODS AND MATERIALS

### Study design

Seventeen radiation oncologists in Europe, Asia, Australasia and North America who were considered to be experts in the treatment of lung cancer were invited to participate in this study. Radiation oncologists who were invited to participate had to be members of the International Association for the Study of Lung Cancer and to be also actively involved in research in radiotherapy for lung cancer. All were attached to academic centers, had experience in treating patients with postoperative radiotherapy, and had access to CT-based treatment planning for this purpose. Each participating expert was asked to contour his/her current routine CTV for 2 patients eligible for PORT. For contouring purposes, a CD-ROM-based validated contouring program was provided (16), which contained complete CT datasets (slice thickness 2.5 mm) of both patients and a tutorial regarding use of the contouring program in PowerPoint format (MS Office). In addition, relevant patient details were provided in the first mailing. The CTVs were contoured using standardized window level settings and saved to the CD-ROM, which was then mailed to the study coordinator. Subsequently, details of the contouring protocol for Lung ART were mailed to experts approximately 2 weeks after response to the initial mailing, to derive a second set of contours (protocol CTV) of the same 2 patients. Contours from each observer were copied (made anonymous) to a template CT dataset of the corresponding patient (Fig. 1).

**Patient 1 (post-lobectomy).** The first patient had undergone a radical right upper lobectomy with a mediastinal lymph node dissection for a stage pT<sub>2</sub>N<sub>2</sub>M<sub>0</sub> tumor. Histology revealed a 3-cm adenocarcinoma with extension to the visceral pleura. Hilar nodes showed no metastases, but two out of seven explored ipsilateral mediastinal nodes (stations 4 and 7 right) showed tumor deposits (17) (Fig. 2). Adjuvant treatment consisted of administration of four cycles of systemic chemotherapy, after which the patient was referred for PORT.

**Patient 2 (post-pneumonectomy).** The second patient had received induction chemotherapy (three cycles of a platinum-based combination) for a 5-cm nodule in the right upper lobe extending to the visceral pleura, with both ipsilateral hilar and subcarinal nodal disease. As response evaluation revealed a partial response of the

tumor and no hilar abnormalities, a right pneumonectomy and mediastinal dissection was performed. Nine lymph nodes were explored: three intrapulmonary and hilar nodes, two subcarinal nodes (station 7), and four paratracheal nodes (2 station 4R and 2 station 2R). Histology revealed a poorly differentiated large-cell carcinoma measuring 4 cm in diameter with 50% necrosis. Metastases were found in a subcarinal node and a right paratracheal node (station 4R). All resection margins were free of tumor, and the patient was referred for PORT for a stage pT<sub>2</sub>N<sub>2</sub>M<sub>0</sub> tumor.

**Lung ART contouring protocol (Appendix A).** The CTV includes the bronchial stump, the ipsilateral hilar node region, and any possible extension to the mediastinal pleura adjacent to the resected tumor bed. In addition, the mediastinal CTV is to include all the lymph nodes that lie between two noncontiguous nodal stations that have contained metastases at any stage. Based on the surgical literature, subcarinal (LN7) and ipsilateral paratracheal nodes (LN4) are always included in the CTV (Fig. 2). In the case of left-sided tumors, the subaortic and para-aortic nodes (LN 5 and 6) should be included in the CTV (Fig. 2). When metastases are identified in a nodal station, the next nodal station superior to it is included in the CTV, as is the nodal station immediately inferior to the lower involved mediastinal node. However, in some cases the volumes delineated for the CTV could become too large. For instance, in the case of LN7 involvement, LN8 should theoretically be included so that the lower limit will be at the gastroesophageal junction. Therefore, it was decided to define the boundaries more clearly in a table (Appendix B).

### Analysis of clinical target volumes

Volumes of the routine and protocol contoured targets of each observer were determined, using a tracing tool in ImageJ (<http://rsb.info.nih.gov/ij/>). The outlines of all axial two-dimensional contours were traced, and the number of encompassed internal pixels (pixel-size 0.87\*0.87 mm) and the number of contoured slices (slice thickness 2.5 mm) were calculated. In addition, both length in three orthogonal directions and center-of-mass (COM) coordinates of each CTV were determined. To determine the coverage of nodal stations to be included in the CTV, a gold standard for mediastinal nodal regions was generated by two clinicians (F.S. and S.S.) at the VU University Medical Center for both patients according to the definitions by Chapet *et al.* (18) using Eclipse v8.1 software (Varian Med. Systems, Palo Alto, CA).

### Dosimetric analysis

To evaluate the influence of contouring variation on dose-volume histogram (DVH) statistics before and after use of the protocol, a dosimetric analysis was performed based on both the smallest and the largest target volume. Planning target volumes (PTVs) were generated by expanding CTVs with a margin of at least 5 mm in the mediolateral and dorsoventral directions and of 10 mm in the craniocaudal direction to account for tumor motion and variations in patient setup. A routine conformal treatment plan consisting of five fields using 6- to 15-mV photons was designed in Eclipse v8.1, based on a gold standard CTV contoured by the principal investigator (S.S.). The Lung ART protocol prescribed a dose of 54 Gy in daily fractions of 2.0 Gy. This plan was then projected on each PTV (smallest and largest routine and protocol PTV) and adjusted such that the 95% isodose volume tightly conformed the PTV while respecting dose constraints to organs at risk according to International Commission on Radiation Units and Measurements objectives (19). Specifically, it was aimed to limit the percentage volume of lung tissue outside the PTV planned to receive 20 Gy to 35% ( $V_{20} \leq 35\%$ ) and the maximum spinal cord dose to 50 Gy. The DVHs were calculated to evaluate variability in toxicity




Fig. 1. Routine clinical target volumes (CTVs) (upper panel) and protocol CTVs (lower panel) from six observers projected on a digital reconstruction of a computed tomography dataset from the postlobectomy patient.

profile, and the following parameters were assessed: mean lung dose, total lung volume minus PTV receiving either  $\geq 20$  Gy ( $V_{20}$ ) or  $\geq 5$  Gy ( $V_5$ ), total cardiac volume percentage receiving  $\geq 45$  Gy ( $V_{45}$ ), maximum spinal cord dose, and esophageal length receiving  $\geq 45$  Gy.

#### Statistical analysis

The variance between routine and protocol CTVs of different observers was assessed by constructing a mixed-effects model

for each endpoint (*i.e.*, volume, length, or COM position). Contouring procedure and patient identifier were taken as fixed effects, whereas the observer identifier was taken as the random grouping variable. Significance was reported at levels 0.05 and 0.007, with the latter being the adjusted value for multiple testing using the Bonferroni method. Differences in nodal coverage between routine and protocol CTVs were evaluated using an F test in Excel (Microsoft Office 2003).

## RESULTS

#### Number of datasets received

For each case, a total of 10 clinicians generated routine clinical target volumes (CTV); they included the principal investigator, who had knowledge of the protocol. Both routine and protocol CTV's for both patients were available from six expert observers. One participating clinician returned only a protocol CTV for both cases because the center did not perform routine PORT.

#### Analysis of clinical target volumes

Regarding experts who returned routine and protocol datasets, for the postlobectomy patient, the median routine CTV was 90.2 cc (range, 36.2–678.4 cc), and the median corresponding protocol CTV was 91.3 cc (range, 60.0–112.4 cc). For the postpneumectomy patient, the median routine CTV was 115.5 cc (range, 48.5–712.1 cc), and the median corresponding protocol CTV was 93.3 cc (range, 78.3–125.3). Regarding all experts, routine CTVs varied up to threefold between clinicians, but this variance was significantly reduced




Fig. 2. Nodal staging system (Mountain-Dresler).




Fig. 3. Routine vs. protocol clinical target volumes (CTVs) (cc) from six observers for the postlobectomy patient (upper panel) and the postpneumectomy patient (lower panel).

for both cases when clinicians used the Lung ART protocol ( $p < 0.007$ ) (Fig. 3). In addition, both the variance in cranial-caudal COM positions ( $p < 0.007$ ) and contoured target lengths along the cranial-caudal Z axis were significantly reduced ( $p < 0.05$ ) using the protocol. All results maintained significance when data of the observer with the most deviating CTV were excluded from analysis.

In both patients, the Lung ART protocol required the CTV to include nodal stations 2 right (LN2R), 4 right (LN4R), 7 (LN7), and ipsilateral hilus. Median coverage of LN4R and LN7 by routine CTVs were 82% (range, 44–97%) and 94% (range, 20–100%), respectively, for the postlobectomy patient. Use of the protocol resulted in an increased median coverage of LN4R ( $p < 0.05$ ) (Fig. 4). Although median coverage did not significantly improve in LN7, the range between observers was much smaller with the protocol (73–100%) compared with routine (20–100%) contoured CTVs (Fig. 4). Similar results were seen in the postpneumectomy patient (Fig. 4). Median coverage of LN2R by routine CTVs was poor in both cases, with values of 0% (range, 0–47%) and 38% (range, 0–62%) in the postlobectomy and postpneumectomy patients, respectively. The results did not significantly improve using the protocol (Fig. 4).

#### Dosimetric analysis

The difference in 95% isodose volume between the smallest and the largest CTV was reduced from 1,802 cc to 216 cc in the postlobectomy patient and from 1,342 cc to 53 cc in the postpneumectomy patient. Variations in routine CTVs led to important differences in the risk of radiation-induced toxicity; *i.e.*, the  $V_{20}$  ranged from 12.7% to 54% in the postlobectomy patient, whereas corresponding values in the postpneumectomy patient ranged from 1.5% to 20.6% (Table 1). Similarly, large variations between experts were observed in mean lung dose, lung  $V_5$ , and cardiac  $V_{45}$  in both cases. When the protocol was used, differences between observers were significantly reduced, resulting in a more consistent toxicity profile (Table 1). The differences in both spinal cord doses and esophageal length receiving  $> 45$  Gy between routine and protocol CTVs were not as striking as seen with the other parameters.

#### DISCUSSION

Studies planned to evaluate PORT should use not only modern radiotherapy techniques but also consistent target volume definition. The latter is particularly relevant because the lack of standardized protocol definitions in the past may




Fig. 4. Nodal coverage (%) by routine and protocol clinical target volumes in the postlobectomy patient (left) and the post-pneumectomy patient (right).

have contributed to inconclusive results (10, 20); i.e., the total dose was often not standardized and excessively high (5), with variable field sizes influencing both local recurrence rates and radiotherapy-induced mortality (6). The results of the present study show that even among thoracic radiation oncology experts, large variability was observed in routine target definition for PORT, and the up to threefold variation resulted in important differences in DVH parameters. The potential influence of pulmonary and cardiac toxicity, arising from unnecessarily large fields, on the risk of radiotherapy-induced mortality is now well appreciated (6). Similar concerns are experienced with the use of adjuvant chemotherapy, which is presently the standard of care in patients with non-small-cell lung cancer and resected N1 and N2 disease (21). Follow-up after more than 5 years after adjuvant chemotherapy revealed an increase in mortality (22), a development that highlights the potential for long-term hazards after any adjuvant therapy for such patients.

Before the commencement of the Lung ART trial, protocol target volumes were developed by the Lung ART writing committee based on patterns of local recurrence after surgery (23, 24), lymphatic pathways, and results of the omission of elective nodal irradiation (25, 26). The present study revealed that use of the Lung ART protocol resulted in a large degree

of consensus between clinicians. However, residual interobserver variability may still exist as a result of misinterpretation, lack of clear formulation, or ignorance of the protocol. This is supported by the finding that use of the protocol did not improve coverage of the upper para-aortal nodes (LN2R). Consequently, a clear definition of the boundaries of this particular region should be specified in the protocol.

Recent major intergroup trials have also included dummy runs as a part of QA analysis (27–32), but these studies differ from ours in that we investigated interobserver variability both before and after the protocol was provided, allowing for evaluation of the impact of the protocol. In addition, earlier dummy runs were performed using hard copies, whereas we used a CD-ROM-based contouring program containing complete CT datasets that can be run automatically on each Windows-based computer. Our previous study validating this CD-ROM tool has established a more realistic assessment of clinical variations than with hard copies, and it was shown that most clinicians were able to complete the exercise (16).

One limitation of our study is that none of the invited experts from North America finally participated in this study. Furthermore, experts were arbitrarily identified from members of International Association for the Study of Lung Cancer and European Organisation for Research and

Table 1. Variability in planning parameters between the smallest and largest target volumes

	Postlobectomy patient				Postpneumectomy patient			
	Routine		Protocol		Routine		Protocol	
	Range	Difference	Range	Difference	Range	Difference	Range	Difference
Planning target volume (cc)	148–1,342	(1,194)	297–382	(85)	187–1,262	(1,075)	275–308	(33)
95% Isodose volume (cc)	300–2102	(1,802)	518–734	(216)	446–1,788	(1,342)	556–609	(53)
Lung								
Mean lung dose (Gy)	8.0–26.1	(18.1)	11.6–15.3	(3.7)	3.4–13.4	(10.0)	4.0–4.1	(0.1)
V <sub>20</sub> (%)	12.7–54.0	(41.3)	20.6–29.2	(8.6)	1.5–20.6	(19.1)	2.1–2.9	(0.8)
V <sub>5</sub> (%)	34.7–79.5	(44.8)	52.2–63.1	(10.9)	31.6–59.3	(27.7)	30.4–35.7	(5.3)
Heart								
V <sub>45</sub> (%)	0–20.5	(20.5)	1.6–5.1	(3.5)	4.3–37.0	(32.7)	7.1–10.0	(2.9)
Spinal cord								
D <sub>max</sub>	45.3–49.5	(4.2)	47.8–50.0	(2.2)	50.0–51.0	(1.0)	44.8–48.7	(3.9)
Esophagus								
Length receiving 45 Gy (cm)	4.5–11.5	(7.0)	6.8–9.5	(2.8)	5.8–12.0	(6.3)	7.5–10.8	(3.3)

Treatment of Cancer who were active in lung cancer and who were known to the study group. In addition, the participating experts themselves did not perform treatment planning; therefore, interinstitution variability in dose statistics could not be assessed. Instead, dosimetric impact of contouring variability was evaluated by designing a standard plan in our own institution, although we believe that this was of minor influence, as contouring variation seems to be the largest source of systemic errors in lung cancer (33). Furthermore, the results are based on a routine conformal plan consisting of five fields, whereas the use of three fields (which is allowed in the protocol) may have resulted in a more forgiving situation, leading to less striking differences between routine and protocol target volumes. In addition, this study did not account for interobserver variability with respect to shape of the contours, which has been reported to be imprecise between observers (34). Other factors besides the Lung ART protocol could have contributed to the reduction in contouring variability over a period of time, including test–retest reliability. We were unable to study the latter because the logistic difficulties involved in obtaining the full cooperation of all the invited experts were considerable.

This dummy run test was part of the first phase of an external QA program, and the results were sent to the QA team for protocol validation. The magnitude of the observed differences led to a decision to invest in a web-based dummy run for the Lung ART trial. This ongoing study will address the above issues in a more representative population of thoracic radiation oncologists. The next step will include collection of the plans and its verification images for the first patient from each participating center. Subsequently, 15% of the plans will be collected by the QA team to ensure protocol adherence in centers where plans of the first patients were adequate, whereas plans of the patients included in the RT arm will be considered for revision in centers where plans were not adherent to the protocol.

## CONCLUSIONS

The large interobserver variation in target definition seen among experts is a confounding factor in clinical outcomes of multicenter clinical trials, emphasizing the need for standardization. A protocol defining target definitions was shown to serve this purpose and is therefore incorporated in the QA program of the Lung ART.

## REFERENCES

- Stephens RJ, Girling DJ, Bleehen NM, *et al.* The role of postoperative radiotherapy in non-small-cell lung cancer: A multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. *Br J Cancer* 1996;74:632–639.
- Mayer R, Smolle-Juettner FM, Szolar D, *et al.* Postoperative radiotherapy in radically resected non-small cell lung cancer. *Chest* 1997;112:954–959.
- Trodella L, Granone P, Valente S, *et al.* Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: Definitive results of a phase III randomized trial. *Radiother Oncol* 2002;62:11–19.
- Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. *Lancet* 1998;352:257–263.
- Machtay M, Lee JH, Shrager JB, *et al.* Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. *J Clin Oncol* 2001;19:3912–3917.
- Miles EF, Kelsey CR, Kirkpatrick JP, *et al.* Estimating the magnitude and field-size dependence of radiotherapy-induced mortality and tumor control after postoperative radiotherapy for non-small-cell lung cancer: Calculations from clinical trials. *Int J Radiat Oncol Biol Phys* 2007;68:1047–1052.
- Uno T, Sumi M, Kihara A, *et al.* Postoperative radiotherapy for non-small-cell lung cancer: Results of the 1999–2001 patterns of care study nationwide process survey in Japan. *Lung Cancer* 2007;56:357–362.
- Lally BE, Zelterman D, Colasanto JM, *et al.* Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. *J Clin Oncol* 2006;24:2998–3006.
- Douillard JY, Rosell R, De Lena M, *et al.* Impact of postoperative radiation therapy on survival in patients with complete resection and Stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. *Int J Radiat Oncol Biol Phys* 2008;72:695–701.
- Le Pécoux C, Dunant A, Pignon JP, *et al.* Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. *J Clin Oncol* 2007;25:e10–e11.
- Keller SM, Adak S, Wagner H, *et al.* A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. *N Engl J Med* 2000;343:1217–1222.
- van de Steene J, Linthout N, de Mey J, *et al.* Definition of gross tumor volume in lung cancer: Inter-observer variability. *Radiother Oncol* 2002;62:37–49.
- Senan S, van Sörnsen de Koste J, Samson M, *et al.* Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. *Radiother Oncol* 1999;53:247–255.
- Bowden P, Fisher R, Mac Manus M, *et al.* Measurement of lung tumor volumes using three-dimensional computer planning software. *Int J Radiat Oncol Biol Phys* 2002;53:566–573.
- Giraud P, Elles S, Helfre S, *et al.* Conformal radiotherapy for lung cancer: Different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. *Radiother Oncol* 2002;62:27–36.
- van Sörnsen de Koste JR, Senan S, Underberg RW, *et al.* Use of CD-ROM-based tool for analyzing contouring variations in involved-field radiotherapy for Stage III NSCLC. *Int J Radiat Oncol Biol Phys* 2005;63:334339.
- Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. *Chest* 1997;111:1718–1723.
- Chapet O, Kong FM, Quint LE, *et al.* CT-based definition of thoracic lymph node stations: An atlas from the University of Michigan. *Int J Radiat Oncol Biol Phys* 2005;63:170–178.
- ICRU report 62: Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU report 50). Bethesda, MD: International Commission on Radiation Units and Measurements; 1999.

20. Bonner JA, Spencer SA. Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy. *J Clin Oncol* 2006;24:2978–2980.
21. Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer: The smoke clears. *N Engl J Med* 2005;352:2640–2642.
22. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. *J Clin Oncol* 2008;26:3552–3559.
23. Ichinose Y, Kato H, Koike T, et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: Questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. *Lung Cancer* 2001;34:29–36.
24. DiBiase SJ, Werner-Wasik M, Croce R, et al. Standard off-cord lung oblique fields do not include the entire mediastinum: A computed tomography simulator study. *Am J Clin Oncol* 2000;23:249–252.
25. Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. *Am J Clin Oncol* 2007;30:239–244.
26. Senan S, Burgers S, Samson MJ, et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. *Int J Radiat Oncol Biol Phys* 2002;54:999–1006.
27. Davis JB, Reiner B, Dusserre A, et al. Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: The dummy run. *Radiother Oncol* 2002;64:65–73.
28. Foppiano F, Fiorino C, Frezza G, et al. The impact of contouring uncertainty on rectal 3D dose-volume data: Results of a dummy run in a multicenter trial (AIROPROS01-02). *Int J Radiat Oncol Biol Phys* 2003;57:573–579.
29. Seddon B, Bidmead M, Wilson J, et al. Target volume definition in conformal radiotherapy for prostate cancer: Quality assurance in the MRC RT-01 trial. *Radiother Oncol* 2000;56:73–83.
30. Widder J, Sedlmayer F, Stanek C, et al. Quality assurance in preoperative radiotherapy of rectal cancer: Evaluation of a pre-trial dummy-run. *Radiother Oncol* 2000;56:341–347.
31. Kouloulis VE, Giraud JY, Davis BJ, et al. Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: The dummy run. *Radiother Oncol* 2004;73:11–20.
32. Coles CE, Hoole AC, Harden SV, et al. Quantitative assessment of inter-clinician variability of target volume delineation for medulloblastoma: Quality assurance for the SIOP PNET 4 trial protocol. *Radiother Oncol* 2003;69:189–194.
33. Weiss E, Hess CF. The impact of gross tumor volume (GTV) and clinical target volume (CTV) definition on the total accuracy in radiotherapy theoretical aspects and practical experiences. *Strahlenther Onkol* 2003;179:21–30.
34. Cooper JS, Mukherji SK, Toledano AY, et al. An evaluation of the variability of tumor-shape definition derived by experienced observers from CT images of supraglottic carcinomas (ACRIN protocol 6658). *Int J Radiat Oncol Biol Phys* 2007;67:972–975.

## APPENDIX A: CONFORMATIONAL POSTOPERATIVE RADIOTHERAPY

According to randomization, patients will receive or not receive postoperative radiotherapy (PORT). We recommend that patients randomized in the treatment arm start PORT as soon as possible after randomization. No concomitant chemotherapy is allowed. At least 10 days' interval between the last day of chemotherapy and PORT is requested. This interval may be extended in case radiosensitizing drugs such as gemcitabine have been used, or when the patient does not have full haematologic recovery from the chemotherapy.

### Radiotherapy technique

High-energy photons ( $\geq 6$  MV) should be used. The planned dose to the International Commission on Radiation Units and Measurements reference point is 54 Gy in 27 fractions of 2.0 Gy. The radiotherapy will be given once each day, 5 days per week. The use of conformal techniques is mandatory. A planning computed tomography (CT) scan in treatment position should be used, with a maximal slide thickness of 5 mm for the whole thorax. The use of intravenous contrast is recommended. All target volumes as well as the critical organs should be delineated on this CT scan. Dose-volume histograms (DVH) of all target volumes—resected clinical tumor volume (rCTV), clinical target volume (CTV), and planning target volume (PTV)—and of all critical organs (lungs, cardiac volume, and spine, with or without esophagus) as described in the following section are required. All patients should be treated with a minimum of three fields. All fields should be treated daily.

### Definition of volumes

*rCTV in the mediastinum.* This corresponds to lymph nodes involved according to the pathologic report of the lymph node exploration. The bronchial stump, the homolateral hilar node region, and the eventual extension to mediastinal pleura facing the resected tumor bed completely resected will always be included in the rCTV.

*CTV in the mediastinum.* In the CTV will be included the rCTV plus a margin corresponding to the upper and lower lymph node station to the involved lymph node area. All the lymph nodes that lie between two noncontiguous node stations that are involved will be included in the CTV. Because of the frequent involvement of subcarinal (LN7) and paratracheal nodes (LN4) on surgical series, these stations will also be systematically included in the CTV.

In the case of a left-sided tumor, the subaortic and the para-aortic nodes (LN 5 and 6) should also be included in the CTV because they are very often involved (as shown in Appendix B). The homolateral supraclavicular region will not be included systematically in the CTV.

*PTV.* Owing to organ movements and to setup uncertainties, an additional margin of at least 0.5 cm (lateral, anterior, and posterior) and 1 cm (superior and inferior) is recommended. The margins may be individualized according to 4D-CT scan data and/or measurements of the daily setup error. For patients who have had a positron emission tomography (PET)—CT scan before treatment, all data will be collected concerning positive nodes. However, only surgical positive nodes will be included in the rCTV.

## APPENDIX B

---

Surgically involved mediastinal nodes	LN stations to be included in the CTV
1-2R	1-2R, 4R, 7, 10R Maximal upper limit: 1 cm above sternal notch but homolateral subclavicular node station may be treated if needed Maximal lower limit: 4 cm below the carina*
1-2L	1-2L, 4L, 7, 10L Maximal upper limit: 1 cm above the sternal notch but homolateral subclavicular node station may be treated if needed Maximal lower limit: 4 cm below the carina*
3 (Right-sided tumor)	3, 4R, 7, 10R Maximal upper limit: 1 cm above the sternal notch Maximal lower limit: 4 cm below the carina*
3 (Left-sided tumor)	3, 4L, 7, 10L Maximal upper limit: 1 cm above the sternal notch Maximal lower limit: 4 cm below the carina*
4R	2R, 4R, 7, 10R Maximal upper limit: sternal notch Maximal lower limit: 4 cm below the carina*
4L	2L, 4L, 7, 10L Maximal upper limit: sternal notch Maximal lower limit: 4 cm below the carina*
5	2L, 4L, 5, 6, 7 Maximal upper limit: top of aortic arch Maximal lower limit: 4 cm below the carina*
6	2L, 4L, 5, 6, 7 Maximal upper limit: sternal notch Maximal lower limit: 4 cm below the carina*
7 (Right-sided tumor)	4R, Maximal upper limit: top of aortic arch Maximal lower limit: 5 cm below the carina*
7 (Left-sided tumor)	4L, 5, 6, 7 Maximal upper limit: top of aortic arch Maximal lower limit: 5 cm below the carina*
8 (Right-sided tumor)	4R, 7, 8 Maximal upper limit: top of aortic arch The lower limit should be the gastroesophageal junction
8 (Left-sided tumor)	4L, 5, 6, 7 8 Maximal upper limit: top of aortic arch The lower limit should be the gastroesophageal junction

---

*Abbreviations:* LN = lymph node; CTV = clinical target volume.

\* Unless other nodes are involved.



ELSEVIER

Brachytherapy ■ (2010) ■

BRACHYTHERAPY

# High-dose rate brachytherapy alone in postoperative soft tissue sarcomas with close or positive margins

Q1

Q2 Jun Itami<sup>1,\*</sup>, Minako Sumi<sup>1</sup>, Yasuo Beppu<sup>2</sup>, Hirokazu Chuman<sup>2</sup>, Akira Kawai<sup>2</sup>,  
Naoya Murakami<sup>1</sup>, Madoka Morota<sup>1</sup>, Hiroshi Mayahara<sup>1</sup>, Ryoichi Yoshimura<sup>1</sup>, Yoshinori Ito<sup>1</sup>,  
Yoshikazu Kagami<sup>1</sup>

Q3

<sup>1</sup>Division of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan

<sup>2</sup>Department of Orthopaedics, National Cancer Center Hospital, Tokyo, Japan

## ABSTRACT

Q4

**PURPOSE:** In the management of soft tissue sarcomas, perioperative radiation therapy has been used to reduce the risk of local recurrence after resection. However, a significance of postoperative high-dose rate brachytherapy (HDRBT) remains to be studied. Retrospective analysis was performed to elucidate the role of postoperative HDRBT.

**METHODS AND MATERIALS:** Twenty-five patients with 26 soft tissue sarcoma lesions underwent postoperative HDRBT using <sup>192</sup>Ir remote afterloader without external beam radiation therapy. Ninety-two percent of the lesions were Grade 2 or 3 malignancies, and 50% were resected with positive surgical margins. The remaining 50% had very close margins. Fourteen lesions were treated for local recurrences after previous resections. Applicators of HDRBT were placed during the operation to include only the tumor bed excluding surgical scars. Applied dose was mainly 36 Gy/6 fractions/3 d b.i.d.

**RESULTS:** Five-year local recurrence-free survival was 78.2% in all the 26 lesions. Recurrences were not seen within the treated volume of HDRBT. Two groups were defined according to the marginal status and number of previous operations. Group 1 was the lesions with a positive margin and foregoing resections. The remaining lesions were classified as Group 2. Five-year local recurrence-free survival was 43.8% and 93.3% in Group 1 and Group 2, respectively with a statistically significant difference ( $p = 0.004$ ).

**CONCLUSIONS:** Postoperative HDRBT was effective in controlling local lesions; but in Group 1 lesions, addition of a wide field external beam radiation therapy seems to be necessary to improve the local control rate. © 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Q5 **Keywords:**

High-dose rate brachytherapy; Soft tissue sarcoma; Postoperative radiation

## Introduction

In the management of soft tissue sarcomas (STSs), surgical resection is the mainstay of treatment. However, local recurrence is seen frequently, especially in the patients with positive surgical margins, a large tumor, and/or recurrence after foregoing surgery (1, 2). Post- or preoperative radiation therapy has been demonstrated to

be effective in reducing the risk of local recurrence (2–4). Furthermore, the combination of surgery and perioperative radiation therapy has changed the management policy of the STSs from a mutilating radical amputation to limb-sparing therapy. External beam radiation therapy (EBRT) is the most frequently used method of radiation therapy, whereas postoperative radiation therapy using low-dose rate brachytherapy (LDRBT) has been reported to be also effective in lowering the local recurrence rate (3, 5). In contrast, postoperative high-dose rate brachytherapy (HDRBT) of STS has been published only sporadically and its clinical significance in the management of STSs remains to be studied (6–10). In National Cancer Center Hospital, HDRBT has been used without EBRT in the postoperative radiation therapy of patients with STSs, whose

Received 19 June 2009; received in revised form 15 July 2009; accepted 20 July 2009.

\* Corresponding author. Division of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. Tel.: +81-3-3542-2511; fax: +81-3-3547-5291.

E-mail address: jitami@ncc.go.jp (J. Itami).

1538-4721/\$ - see front matter © 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.  
doi:10.1016/j.brachy.2009.07.012

removal seemed to result in a resection with positive or close margins. In this study, the role and significance of postoperative HDRBT alone in the management of STS is analyzed retrospectively.

### Methods and materials

**Q6** From 1995 to 2008, 25 patients with 26 STS lesions underwent postoperative HDRBT alone in National Cancer Center Hospital. There were 10 men and 15 women. In a male patient with malignant fibrous histiocytoma, the lesion was managed with operation and postoperative HDRBT and the tumor recurred proximal to the original site. The recurred tumor was resected and postoperative HDRBT was administered repeatedly (Table 1). Median age was 60.7 years ranging from 9 to 76 years. Primary sites of the tumors were upper extremity with 12 lesions and lower extremity with 11 lesions. Primary truncal STS was seen in three lesions. As for pathology, malignant

fibrous histiocytoma was most frequently seen in 12 lesions followed by leiomyosarcoma in three lesions. Eighty-eight percent of lesions were diagnosed as Grade 2 or 3 in three-tiered grade classification. Surgical margins were microscopically positive for sarcoma cells in 13 lesions; whereas in 13 lesions, resection margins were very close (less than 5 mm) to the tumor because of the proximity of the tumor to the functionally important structures, such as major neurovascular bundles, made it difficult to attain adequate surgical margins. The maximal tumor size in the pathologic specimen was 9 cm in a mean with a range between 1.2 cm and 22 cm. Included in the present study were also the STSs, which recurred after previous surgeries. Fourteen lesions were treated by resections and HDRBTs for recurrences after the previous surgeries. Number of the foregoing surgeries ranged from one to eight.

Indication of the postoperative HDRBT was determined preoperatively by a joint meeting of orthopedic surgeons and radiation oncologists. Postoperative HDRBT was used to preserve major neurovascular bundles or major muscles, which are indispensable to maintain the functional integrity of extremities. During the operation, resection margins close to or contaminated by tumor were confirmed by both orthopedic surgeons and radiation oncologists. Surgical clips were placed to delineate the tumor bed as well as the resection margins very close to the lesion. The flexible applicator tubes of HDRBT were placed to cover the tumor bed with 1–2 cm margins in a parallel fashion with 1–1.5 cm intervals between the tubes. Applicator tubes have a closed end and were sutured to the tumor bed. The open ends of tubes were pulled through the skin and connected to the remote afterloading machine. Muscular or adipose tissue flaps of about 5 mm thickness were used to cover major nerve and/or vascular bundles to avoid direct contact of the applicators. The tubes were removed after completion of the HDRBT. Radiation therapy planning was performed by Plato (version 14.3.7; Nucletron, Veenendaal, The Netherlands). The coordinates of the tube applicators were digitized using orthogonal x-rays and/or CT images. The dwell positions of HDRBT source were located to cover tumor bed encircled by the surgical clips. No special efforts were exerted to include all the scar and drainage sites. Geometric optimization was used to calculate dwell times with a reference point of 5 mm lateral to the midportion of the central tube applicator. For HDRBT,  $^{192}\text{Ir}$  afterloading machine was used (microSelectron HDR; Nucletron, Veenendaal, The Netherlands). All the lesions but one were irradiated with a fractional dose of 6 Gy, and the remaining one was treated by 4.5 Gy because neighboring nerve could not be adequately protected by the flap. The HDRBT was done b.i.d. with an interval between the fractions of at least 6 h. Six fractions were administered in all but one lesion, which was treated with four fractions because of the accidental early slip out of the applicators. In 24 lesions, applied dose was 36 Gy, 30 Gy, and 27 Gy each in one lesion (Table 2). Interval

Table 1  
Age and sex of the 25 patients and characteristics of the 26 lesions undergoing postoperative high-dose rate brachytherapy for soft tissue sarcomas

Characteristics	Number/ratio
Median age (y)	60.7 (range, 9–76)
Sex	
Male:female	11:15
Primary Site	
Upper extremity	12
Lower extremity	11
Trunk	3
Histopathology	
Malignant fibrous histiocytoma	12
Leiomyosarcoma	3
Synovial sarcoma	3
Liposarcoma	2
Rhabdomyosarcoma	2
Others	4
Malignant grade	
1	2
2	9
3	15
Tumor size	
Mean	9 cm (range, 1.2–22)
<5 cm	9
>5 cm	17
Number of previous operations	
0	12
>1	14
Status of surgical margin	
Positive	13
Negative	13
Chemotherapy	
Yes	12
No	14

Table 2  
Postoperative high-dose rate brachytherapy for soft tissue sarcomas

Characteristics	Number
Interval between OP and BT (days)	
Mean	5.3 (range, 1–7)
<5	2
>5	24
Median number of applicators	7 (range, 2–15)
Fractional dose	
4.5 Gy	1
6 Gy	25
Number of fractions	
5	1
6	25
Total dose (EQD2 for tumor control)	
27 Gy (32.6 Gy)	1
30 Gy (40 Gy)	1
36 Gy (48 Gy)	24
Mean volume encircled by the prescribed dose	74.9 cc (range, 18.5–173)

OP = operation; BT = brachytherapy; EQD2 = equivalent dose with 2 Gy fraction.

between the operation and the HDRBT was 5.3 days in a mean, and 24 HDRBTs were commenced between 5 and 7 days after the operation. Number of implanted tube applicators ranged from two to 15 with a median of seven. The treated volume encircled by the prescribed dose ranged from 18.5 to 173 cc with a mean of 74.9 cc. Chemotherapy was delivered in 12 lesions.

Median followup length was 49.7 months ranging from 4.7 to 187 months. Local recurrence-free survival (LRFS) was calculated in the 26 lesions, and overall survival (OS) in all the 25 patients. Local recurrence was defined as a regrowth of the STS within 5 cm from the operation scars. LRFS and OS were calculated by Kaplan–Meier method (11) with a difference between the survival curves evaluated by a logrank test. Acute morbidities seen within 6 months after HDRBT were classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0, whereas Radiation Therapy Oncology Group/European Organization for Research and Treatment for Cancer criteria were used for late morbidities (12).

## Results

Local recurrence was observed in five lesions. All the local recurrences occurred outside of the treated volume of HDRBT. These local recurrences were within the treated volume, if postoperative EBRT were administered encompassing all the surgical scars with 5 cm margins. LRFS of all 26 lesions was 78.2% in 5 years. According to the surgical margin status, 5-year LRFSs of positive and negative margins were 90.9% and 64.6%, respectively, without




Fig. 1. Local recurrence-free survivals according to surgical margin status.

a statistically significant difference ( $p = 0.11$ ) (Fig. 1). In the lesions treated as a primary therapy, LRFS is 90.9% in 5 years, whereas the recurrent lesions after previous operations showed 5-year LRFS rate of 66.5% ( $p = 0.15$ ) (Fig. 2). The lesions were classified into two groups according to the surgical margin status and number of foregoing operations. Group 1 was defined as recurrent lesions, which were resected with positive surgical margins. All other lesions were classified into Group 2. There were eight lesions in Group 1 and 18 in Group 2. Five-year LRFS was 43.8% and 93.3% in Group 1 and Group 2, respectively




Fig. 2. Local recurrence-free survivals according to number of previous operations.




Fig. 3. Local recurrence-free survivals according to the group classification by surgical margin status and number of previous operations (for details refer to the text).

(Fig. 3). The difference reached a statistical significance with  $p = 0.004$ . Sex, malignant grade, tumor size, number of applicators, and treated volume were found to have no statistically significant influences on LRFS. In the 23 lesions of the extremity STSs, only one amputation was required to control recurrence.

OS of 25 patients was 75.6% in 5 years. There were only 2 patients with Grade 1 malignancy and both of them were alive without recurrence. The patients with Grade 2 and 3 lesions showed similar OSs and 71.6% of them were alive for 5 years.

Acute morbidities were seen in 7 patients with Grade 1 morbidities in 6 patients and Grade 2 in 1 patient (Table 3). Grade 1 morbidities were a slight bleeding from the scar at the time of applicator removal, slight erosion of skin, and seroma formation requiring aspiration only once or twice. Grade 2 morbidity was wound dehiscence, which healed with conservative measures. Chronic

Table 3

Q9 Number of morbidities of postoperative high-dose rate brachytherapy

Morbidities	Malignant grade	Number of morbidities
Acute morbidity		
Wound complication	1	4
	2	2
Paresthesia	1	1
Seroma formation	1	1
Late morbidity		
Wound complication	2	1
Seroma formation	1	1
Bone exposure	4	1
Infectious fistula	3	1

morbidities were seen in 4 patients. The Grade 3 and 4 morbidity were seen each in 1 patient. Grade 4 morbidity was bone exposure at the HDRBT site requiring surgical removal of the sequester and repair with bone transplantation. The Grade 3 morbidity was fistula formation with an ensuing infection managed by debridement. Both morbidities occurred within 24 months after HDRBT. Five-year rate of chronic morbidities equal to or greater than Grade 2 was 14.6%.

## Discussions

In the management of STS, limb-sparing operation with perioperative radiation therapy has been established as a standard (13). With that combination, LRFS rate is reported to be 75–100% (1–4, 14). However, local recurrence rate is strongly influenced by the surgical margin status, number of previous operations, grade of malignancy, and primary site of STS (1, 2). In the present study, operative margins were microscopically positive in 50% of the patients and the remaining patients had very close margins less than 5 mm. Furthermore, 54% of the lesions were classified as Grade 3 malignancies. Considering the adverse features of this series, LRFS rate of 78.2% in 5 years is relatively favorable. The marginal status, number of the previous operations, and the grade of malignancy did not have an influence on LRFS with a statistical significance, probably because of the small number of the patients in this series. However, the recurrent lesions resected with positive surgical margins showed a poor 5-year LRFS of 43.8% in comparison to the other lesions with 93.3% LRFS in 5 years.

Brachytherapy has an advantage of concentrating dose distribution onto the tumor region with a simultaneous sparing of normal tissues (15), whereas EBRT with wide fields encompassing tumor as well as surgical beds sometimes causes bone fracture, subcutaneous fibrosis, and lymphedema distal to the irradiated site (16). According to Memorial Sloan-Kettering Cancer Center studies, postoperative LDRBT as a single modality reduces local recurrence in margin-negative high-grade STS (1, 3). The LDRBT did not include operative scars and drainage scars in the treated volume. In contrary, local recurrence was not reduced by LDRBT alone in postoperative low-grade STSs (17). They also suggested that high-grade STSs with positive surgical margins are better treated by combination of EBRT and LDRBT (5). Although HDRBT has advantages that radiation dose distribution can be optimized by the manipulation of dwell positions and dwell times of  $^{192}\text{Ir}$  source, and radiation exposure to the medical personnel is negligible, the paucity of reported series makes it difficult to establish the optimal fractionation and total dose of HDRBT (6–10). Retrospective analyses revealed that combined EBRT and HDRBT is well tolerated and reduce local recurrence. Chun *et al.* (6) showed that local recurrence was not seen in 17 patients treated with 12–18 Gy

of 6 fractions of HDRBT combined with EBRT of 36–60 Gy. Pohar *et al.* (9) demonstrated that 2-year local control of 94% could be obtained with HDRBT of 13.5 Gy in three fractions with EBRT. Koizumi *et al.* (7) showed somehow poorer local control rate of 48% in 2 years because of the adverse features of their patients with macroscopic residual disease in 31%. In the present study, HDRBT was used without EBRT. HDRBT was delivered to the tumor bed without including surgical and drainage scars. At the launch of the postoperative HDRBT, radiation was planned to be confined to the tumor bed based on the reports from Memorial Sloan-Kettering Cancer Center. Because most of the patients in this series underwent resections reaching to the major neurovascular bundles and the high-dose radiation to them could cause serious morbidities, the total dose of HDRBT was determined by tolerance dose of peripheral nerve assumed as about 60 Gy in a conventional fractionation. The corresponding biologically equivalent dose by 2 Gy fractionation was calculated by linear quadratic model assuming  $\alpha/\beta = 10$  Gy and 3 Gy for tumor control and late toxicity, including nerve damage, respectively (18). The equivalent dose by 2 Gy fractionation for HDRBT of 36 Gy was 48 Gy and 64.8 Gy, respectively, for tumor control and late toxicity. Because of the favorable results, this field setup and fractionation regimen of HDRBT have been continued to the present time.

Despite the retrospective nature of this study and the small number of patients, HDRBT alone with the fractionation regimens used in this study seems to be satisfactory to sterilize lesions in the treated volume. However, poor LRFS of 43.8% in 5 years demonstrates that in lesions treated for recurrence and whose surgical margins are positive, STSs tended to recur outside of the treated volume of HDRBT but within 5 cm from the surgical scars. It seems that they had better been treated with combination of HDRBT and wide field EBRT encompassing surgical beds as well as scars and drainage sites.

Serious late morbidity was seen in 2 patients, both of which could be repaired by surgical procedures. Although it is recommended to begin brachytherapy no sooner than 5 days after the operation (1, 15), 2 patients irradiated with a shorter interval did not have any serious morbidities. There were no patients who underwent limb amputation because of morbidities.

## Conclusions

In summary, HDRBT alone to the tumor bed without including surgical scars and drainage sites with 36 Gy/6 fractions/3 d seems to be adequate and tolerable as a postoperative treatment for patients initially operated and/or negative for surgical margins. If the lesion is operated for recurrence and surgical margins are positive, administration of wide fields EBRT is recommended.

## Acknowledgment

This work was partly supported by Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare, Japan.

## References

- [1] Pisters PWT, Leung DHY, Woodruff J, *et al.* Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. *J Clin Oncol* 1996;14:1679–1689.
- [2] Zagars GK, Ballo MT, Pisters PWT, *et al.* Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: A retrospective comparative evaluation of disease outcome. *Int J Radiat Oncol Biol Phys* 2003;56:482–488.
- [3] Pisters PWT, Harrison LB, Leung DHY, *et al.* Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. *J Clin Oncol* 1996;14:859–868.
- [4] Yang JC, Chang AE, Baker AR, *et al.* Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. *J Clin Oncol* 1998;16:197–203.
- [5] Alekhteyar KM, Leung DH, Brennan MF, *et al.* The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin. *Int J Radiat Oncol Biol Phys* 1996;36:321–324.
- [6] Chun M, Kang S, Kim BS, *et al.* High dose rate interstitial brachytherapy in soft tissue sarcoma: Technical aspects and results. *Jpn J Clin Oncol* 2001;31:279–283.
- [7] Koizumi M, Inoue T, Yamazaki H, *et al.* Perioperative fractionated high-dose rate brachytherapy for malignant bone and soft tissue tumors. *Int J Radiat Oncol Biol Phys* 1999;43:989–993.
- [8] Martinez-Monge R, San Julian M, Amillo S, *et al.* Perioperative high-dose-rate brachytherapy in soft tissue sarcomas of the extremity and superficial trunk in adults: Initial results of a pilot study. *Brachytherapy* 2005;4:264–270.
- [9] Pohar S, Haq R, Liu L, *et al.* Adjuvant high-dose-rate and low-dose-rate brachytherapy with external beam radiation in soft tissue sarcoma: A comparison of outcomes. *Brachytherapy* 2007;6:53–57.
- [10] Nag S, Porter AT, Donath D. The role of high dose rate brachytherapy in the management of adult soft tissue sarcomas. In: Nag S, editor. *High dose rate brachytherapy. A textbook.* New York, NY: Futura Publishing Company; 1994. p. 393–408.
- [11] Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958;53:457–481.
- [12] Perez CA, Brady LW. Principles and practice of radiation oncology. Philadelphia, PA: JB Lippincott Company; 1993. pp. 53–55.
- [13] Pisters PWT, O'Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. *J Clin Oncol* 2007;25:1003–1008.
- [14] Suit HD, Mankin HJ, Wood WC, *et al.* Treatment of the patient with stage M0 soft tissue sarcoma. *J Clin Oncol* 1988;6:854–862.
- [15] Nag S, Shasha D, Janjan N, *et al.*, American Brachytherapy Society. The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas. *Int J Radiat Oncol Biol Phys* 2001;49:1033–1043.
- [16] Davis AM, O'Sullivan B, Turcotte R, *et al.*, Canadian Sarcoma Group/NCI Canada Clinical Trial Group Randomized Trial. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. *Radiother Oncol* 2005;75:48–53.
- [17] Pisters PWT, Harrison LB, Woodruff JM, *et al.* A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. *J Clin Oncol* 1994;12:1150–1155.
- [18] Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. *Br J Radiol* 1989;62:679–694.